Chargement en cours...
Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor antibody, developed by Bristol-Myers Squibb Inc., has activity across non–small cell lung cancer (NSCLC) histologies and is Food and Drug Administration approved for treatment of metastatic squamous NSCLC with progre...
Enregistré dans:
| Publié dans: | Appl Immunohistochem Mol Morphol |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Lippincott Williams & Wilkins
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4561627/ https://ncbi.nlm.nih.gov/pubmed/26317305 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAI.0000000000000256 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|